Doctors can sue FDA to block abortion pill because it's 'emotionally taxing' to treat women who have taken it: Fifth Circuit

Apr 13, 2023 View Original Article
  • Bias Rating

    -24% Somewhat Liberal

  • Reliability

    65% ReliableFair

  • Policy Leaning

    -30% Medium Liberal

  • Politician Portrayal

    46% Negative

Bias Score Analysis

The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.

Sentiments

Overall Sentiment

N/A

  •   Liberal
  •   Conservative
SentenceSentimentBias
"The court reasoned that the plaintiffs, a group of anti-abortion doctors, therefore had standing to sue to pull mifepristone from the market, a ruling that might well open the floodgates for similar litigation involving other drugs."
Positive
22% Conservative
"But the panel kept in place Kacsmaryk's decision to roll back the U.S. Food and Drug Administration's (FDA) 2016 decision to make the drug more easily available, including by mail, finding that anti-abortion doctors who had treated patients suffering from side effects had been sufficiently injured to justify their lawsuit."
Positive
18% Conservative
"An appeal to the current Supreme Court -- one that is not only exceedingly hostile to abortion, but that is also committed to curtailing the authority of federal administrative agencies -- is unlikely to yield positive results for the Biden administration."
Negative
-16% Liberal
Upgrade your account to obtain complete site access and more analytics below.

Bias Meter

Extremely
Liberal

Very
Liberal

Moderately
Liberal

Somewhat Liberal

Center

Somewhat Conservative

Moderately
Conservative

Very
Conservative

Extremely
Conservative

-100%
Liberal

100%
Conservative

Bias Meter

Contributing sentiments towards policy:

61% : The court reasoned that the plaintiffs, a group of anti-abortion doctors, therefore had standing to sue to pull mifepristone from the market, a ruling that might well open the floodgates for similar litigation involving other drugs.
59% : But the panel kept in place Kacsmaryk's decision to roll back the U.S. Food and Drug Administration's (FDA) 2016 decision to make the drug more easily available, including by mail, finding that anti-abortion doctors who had treated patients suffering from side effects had been sufficiently injured to justify their lawsuit.
42% : An appeal to the current Supreme Court -- one that is not only exceedingly hostile to abortion, but that is also committed to curtailing the authority of federal administrative agencies -- is unlikely to yield positive results for the Biden administration.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.

Copy link